Polypharmacy as risk factor of interdrug interactions and possible cause of pharmacotherapy complications in multidisciplinary pediatric hospital

Drug interactions are a critical problem in clinical pharmacology and daily clinical practice. Physicians often face the need to prescribe a combination of two or more drugs (polypharmacy), especially when treating patients with several comorbidities. In some combinations, drugs, being chemically active substances, can enter into multi-drug interactions often with clinically significant adverse effects and/or reduction of therapy effectiveness, increasing the cost of treatment. Potential multi-drug interaction refers to the possibility of changing the pharmacological effect of one or more drugs when they are prescribed simultaneously or sequentially. Depending on the final result, the interaction may be synergistic (with increasing effect) or antagonistic (weakening or blockage of the effect).

[1]  Н. Б. Лазарева,et al.  Полипрагмазия в педиатрической практике: современные реалии , 2019 .

[2]  S. Bolen,et al.  Outcome measures in pediatric polypharmacy research: a scoping review , 2019, Drugs & Therapy Perspectives.

[3]  R. Boulkedid,et al.  Interrater reliability of a tool to assess omission of prescription and inappropriate prescriptions in paediatrics , 2019, International Journal of Clinical Pharmacy.

[4]  Yi Li,et al.  Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis , 2019, American Journal of Cardiovascular Drugs.

[5]  Emma Barry,et al.  Potentially Inappropriate Prescribing in Children , 2018, Journal of Pediatrics and Pediatric Medicine.

[6]  S. Janković,et al.  Risk factors for potential drug‐drug interactions in intensive care unit patients☆ , 2018, Journal of critical care.

[7]  L. M. Brennan-Bourdon,et al.  Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients , 2017, BMC Pharmacology and Toxicology.

[8]  N. Barnett,et al.  A themed journal issue on deprescribing , 2016, European journal of hospital pharmacy. Science and practice.

[9]  A. Bhagavathula,et al.  Potential drug–drug interactions in pediatric wards of Gondar University Hospital, Ethiopia: A cross sectional study , 2016 .

[10]  G. Murtaza,et al.  Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients , 2015, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[11]  Chris Feudtner,et al.  Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals , 2015, Pediatrics.

[12]  M. Wiese,et al.  The benefits and harms of deprescribing , 2014, The Medical journal of Australia.

[13]  S. Bangalore,et al.  Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials , 2013, BMJ.

[14]  G. Noll,et al.  Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET. , 2009, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[15]  A. Jonville-Béra,et al.  Prescription of drugs contraindicated in children: a national community survey , 2006, European Journal of Clinical Pharmacology.